Broad Effectiveness: Study With Aripiprazole

Otsuka Pharmaceutical Development & Commercialization, Inc.444 enrolled

Overview

The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

444

Conditions

Schizophrenia Schizoaffective Disorder

Interventions

AripiprazoleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

* Patients with Schizophrenia or Schizoaffective Disorder

Locations (1)

Local Institution

Wallingford, Connecticut, United States

Outcomes

Primary Outcomes

Safety Assessments

Secondary Outcomes

Safety Assessments

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.